COMPANY

POP Biotechnologies Inc.

HQ: Buffalo, NY (US office) source · pop.bio ↗ · Mid-Atlantic

POP BIO's SNAP technology is used to make particle-based vaccines and immunotherapies for infectious diseases, cancer, Alzheimer's disease and other conditions. From company website Source · Oct 12, 2026

Keywords: Vaccine infectious

Location: Buffalo, NY (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

21NIH grants

Funding and NIH signals

NIH award NIH awarded $310K (STTR Phase I 1R41HL184798-01A1, new, notice Jul 31, 2026); 3 NIH awards totaling $2.08M in the last 12 months. NIH RePORTER 1R41HL184798-01A1 (Jul 31, 2026)
Evidence (3 events)
- Jul 31, 2026 · NIH RePORTER 1R41HL184798-01A1
  Organization: POP BIOTECHNOLOGIES, INC; City/State: BUFFALO, NY; Project number: 1R41HL184798-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-31; FY total cost (award amount): 309794; Administering IC: National Heart Lung and Blood Institute; Project title: Liposome-displayed ApoB fragment for active immunotherapy against atherosclerosis; Organization type: Domestic For-Profits
- Jun 26, 2026 · NIH RePORTER 5R44AI181479-03
  Organization: POP BIOTECHNOLOGIES, INC; City/State: BUFFALO, NY; Project number: 5R44AI181479-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 948983; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment; Organization type: Domestic For-Profits
- Jun 25, 2026 · NIH RePORTER 5R42AG082620-04
  Organization: POP BIOTECHNOLOGIES, INC; City/State: BUFFALO, NY; Project number: 5R42AG082620-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 822289; Administering IC: National Institute on Aging; Project title: Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Oct 1, 2025 Grant Government grant: $2.46M (total, as published), announced Oct 1, 2025. Source: company release on GlobeNewswire. source ↗

Funding

Last 2 years.

Oct 1, 2025 Government grant: $2.46M (total, as published), announced Oct 1, 2025. Source: company release on GlobeNewswire. source ↗

NIH awards 21

Annual award amounts. Total $10.9M.

Jul 31, 2026 NIH award 1R41HL184798-01A1 FY2026: $309,794 awarded for that fiscal year; activity R41 (STTR); PI CHYU, KUANG-YUH; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Liposome-displayed ApoB fragment for ac source ↗
Jun 26, 2026 NIH award 5R44AI181479-03 FY2026: $948,983 awarded for that fiscal year; activity R44 (SBIR); PI KUTSCHER, HILLIARD; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Advanced testing of a hexavalent adjuv source ↗
Jun 25, 2026 NIH award 5R42AG082620-04 FY2026: $822,289 awarded for that fiscal year; activity R42 (STTR); PI HUANG, WEI-CHIAO; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Mosaic Display of Multivalent Tau and A- source ↗
Sep 18, 2025 NIH award 2R42AG082620-03 FY2025: $833,334 awarded for that fiscal year; activity R42 (STTR); PI HUANG, WEI-CHIAO; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Mosaic Display of Multivalent Tau and A- source ↗
Jul 30, 2025 NIH award 5R41AI184019-02 FY2025: $300,000 awarded for that fiscal year; activity R41 (STTR); PI XIN, HONG; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Liposome-displayed peptide vaccine against diss source ↗
May 13, 2025 NIH award 5R44AI181479-02 FY2025: $949,201 awarded for that fiscal year; activity R44 (SBIR); PI KUTSCHER, HILLIARD; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Advanced testing of a hexavalent adjuv source ↗
Aug 5, 2024 NIH award 5R41AG082620-02 FY2024: $247,714 awarded for that fiscal year; activity R41 (STTR); PI HUANG, WEI-CHIAO; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Mosaic Display of Multivalent Tau and A- source ↗
Aug 1, 2024 NIH award 1R41AI184019-01A1 FY2024: $300,000 awarded for that fiscal year; activity R41 (STTR); PI XIN, HONG; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Liposome-displayed peptide vaccine against di source ↗
May 31, 2024 NIH award 1R44AI181479-01 FY2024: $950,225 awarded for that fiscal year; activity R44 (SBIR); PI KUTSCHER, HILLIARD; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Advanced testing of a hexavalent adjuv source ↗
Mar 27, 2024 NIH award 1SB1CA288098-01 FY2024: $249,873 awarded for that fiscal year; activity SB1 (SBIR); PI KUTSCHER, HILLIARD; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Clinical Translation of Interstitial C source ↗
Sep 19, 2023 NIH award 6R42CA243954-03 FY2023: $998,596 awarded for that fiscal year; activity R42 (STTR); PI SHAFIRSTEIN, GAL; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Interstitial Chemophototherapy with Ligh source ↗
Sep 14, 2023 NIH award 1R41AG082620-01 FY2023: $248,855 awarded for that fiscal year; activity R41 (STTR); PI HUANG, WEI-CHIAO; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Mosaic Display of Multivalent Tau and A- source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93023C00031-0-9999-1 FY2023: $599,806 awarded for that fiscal year; activity N43 (OTHER_NIH); PI SINGLETON, KENTNER; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. MUL source ↗
Sep 8, 2022 NIH award 2R42CA243954-02 FY2022: $1,001,404 awarded for that fiscal year; activity R42 (STTR); PI SHAFIRSTEIN, GAL; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Interstitial Chemophototherapy with Li source ↗
Jun 29, 2022 NIH award 5R43AI165089-02 FY2022: $299,991 awarded for that fiscal year; activity R43 (SBIR); PI HUANG, WEI-CHIAO; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Developing a Thermostable SARS-CoV-2 RBD source ↗
Jul 9, 2021 NIH award 1R43AI165089-01 FY2021: $299,991 awarded for that fiscal year; activity R43 (SBIR); PI HUANG, WEI-CHIAO; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Developing a Thermostable SARS-CoV-2 RBD source ↗
Apr 6, 2020 NIH award 1R41CA243954-01A1 FY2020: $399,917 awarded for that fiscal year; activity R41 (STTR); PI SHAFIRSTEIN, GAL; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Interstitial Chemophototherapy with Li source ↗
Feb 10, 2020 NIH award 1R41AI149954-01 FY2020: $223,797 awarded for that fiscal year; activity R41 (STTR); PI KUTSCHER, HILLIARD; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. An adjuvanted influenza vaccine platfo source ↗
Apr 22, 2019 NIH award 3R43CA228707-01A1S1 FY2019: $55,000 awarded for that fiscal year; activity R43 (SBIR); PI CARTER, KEVIN A; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Scalable Formulation and Production of source ↗
2019 NIH contract (government contract; not a grant and not an investment round) 75N93019C00011-0-9999-1 FY2019: $599,897 awarded for that fiscal year; activity N43 (OTHER_NIH); PI KUTSCHER, HILLIARD; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. A L source ↗
Sep 6, 2018 NIH award 1R43CA228707-01A1 FY2018: $224,205 awarded for that fiscal year; activity R43 (SBIR); PI CARTER, KEVIN A; recipient as written: POP BIOTECHNOLOGIES, INC, BUFFALO, NY. Scalable Formulation and Production of source ↗